Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin ’s lymphoma patients receiving high ( & gt; 20%) FN-risk chemotherapy: results from a prospective observational study
ConclusionsFN rates were consistent with previous reports with pegfilgrastim in clinical practice. No new ADRs were observed. G-CSF discontinuation was uncommon but appeared to increase the likelihood of neutropenic complications.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Lymphoma | Study